Aclaris Therapeutics, Inc. (ACRS)

NASDAQ: ACRS · IEX Real-Time Price · USD
15.74
+1.07 (7.29%)
At close: Sep 30, 2022 4:00 PM
15.30
-0.44 (-2.80%)
After-hours: Sep 30, 2022 5:43 PM EDT
7.29%
Market Cap 1.05B
Revenue (ttm) 6.14M
Net Income (ttm) -83.27M
Shares Out 66.67M
EPS (ttm) -1.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 278,470
Open 14.80
Previous Close 14.67
Day's Range 14.76 - 16.03
52-Week Range 9.26 - 18.75
Beta 0.60
Analysts Buy
Price Target 35.50 (+125.5%)
Earnings Date Oct 31, 2022

About ACRS

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of ... [Read more...]

Industry Pharmaceuticals
IPO Date Oct 7, 2015
CEO Neal Walker
Employees 72
Stock Exchange NASDAQ
Ticker Symbol ACRS
Full Company Profile

Financial Performance

In 2021, ACRS's revenue was $6.76 million, an increase of 4.30% compared to the previous year's $6.48 million. Losses were -$90.87 million, 78.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ACRS stock is "Buy." The 12-month stock price forecast is 35.5, which is an increase of 125.54% from the latest price.

Price Target
$35.5
(125.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations

WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory d...

5 days ago - GlobeNewsWire

Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

1 month ago - GlobeNewsWire

Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata

WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

1 month ago - GlobeNewsWire

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

1 month ago - GlobeNewsWire

Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to Buy

Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

2 months ago - Zacks Investment Research

Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?

Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

2 months ago - Zacks Investment Research

Aclaris Therapeutics Expands Leadership Team

WAYNE, Pa., June 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

3 months ago - GlobeNewsWire

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.

3 months ago - Zacks Investment Research

Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?

Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the ...

3 months ago - Zacks Investment Research

Does Aclaris (ACRS) Have the Potential to Rally 141% as Wall Street Analysts Expect?

The consensus price target hints at a 141% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate rev...

3 months ago - Zacks Investment Research

Has Aclaris Therapeutics (ACRS) Outpaced Other Medical Stocks This Year?

Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.

3 months ago - Zacks Investment Research

Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference

WAYNE, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

4 months ago - GlobeNewsWire

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 179%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 179.1% in Aclaris (ACRS). While the effectiveness of this highly sought-after metric is questionable, the positiv...

4 months ago - Zacks Investment Research

Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

WAYNE, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory dis...

4 months ago - GlobeNewsWire

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 20.51% and 13.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory dis...

4 months ago - GlobeNewsWire

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -2.78% and 16.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

7 months ago - GlobeNewsWire

Earnings Preview: Aclaris Therapeutics (ACRS) Q4 Earnings Expected to Decline

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference

WAYNE, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

8 months ago - GlobeNewsWire

Aclaris Therapeutics Provides R&D Update

WAYNE, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

8 months ago - GlobeNewsWire

Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference

WAYNE, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

9 months ago - GlobeNewsWire

Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Tr...

WAYNE, Pa., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

9 months ago - GlobeNewsWire

Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021

Investigational New Drug Application for ATI-2138 Allowed

10 months ago - GlobeNewsWire